Protein Sciences Corporation (PSC) announced that it commenced manufacturing of a vaccine to protect humans against the H1N1 “swine flu” virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok®, is made using PSC’s proprietary baculovirus and insect cell manufacturing technology. PSC claims that PanBlok is the first and only vaccine that could be used to protect against the escalating worldwide pandemic, at least for the next few months.
A week after Protein Sciences announced production of its vaccine, several creditors with total claims of about twelve million filed an Chapter 7 petition seeking bankruptcy for Protein Sciences Corporation.
About PSC
PSC is a privately held biopharmaceutical company based in Meriden, Connecticut, manufacturing innovative vaccines and biopharmaceuticals. PSC uses recombinant DNA technology to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. The active ingredients in all of the firm’s products are recombinant proteins that are manufactured, using its patented protein expression technology, based upon baculovirus and insect cell technology.
If you would like to make a comment, please fill out the form below.
Featured Reports
